• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by RxSight Inc. (Amendment)

    6/5/23 4:52:50 PM ET
    $RXST
    Ophthalmic Goods
    Health Care
    Get the next $RXST alert in real time by email
    SC 13D/A 1 d499006dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

     

    RXSIGHT, INC.

    (Name of Issuer)

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

    78349D107

    (CUSIP Number)

    Patrick G. Enright

    Managing Member

    Longitude Capital Partners II, LLC

    2740 Sand Hill Road, 2nd Floor

    Menlo Park, CA 94025

    (650) 854-5700

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 26, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on following pages)

     

     

     


    CUSIP No. 78349D107    13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Longitude Capital Partners II, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      1,491,463 (1)

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      1,491,463 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,491,463 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      4.4% (2)

    14  

      TYPE OF REPORTING PERSON (see instructions)

     

      OO

     

    (1)

    All shares of Common Stock are held of record by LVPII (as defined in Item 2(a) below). LCPII (as defined in Item 2(a) below) is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker, a member of the Issuer’s board of directors and Patrick G. Enright, are the managing members of LCPII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 33,981,877 shares of Common Stock outstanding as of April 28, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the “Commission”) on May 9, 2023 (the “Form 10-Q”).


    CUSIP No. 78349D107    13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Longitude Venture Partners II, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

     

      WC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      1,491,463 (1)

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      1,491,463 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,491,463 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      4.4% (2)

    14  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    All shares of Common Stock are held of record by LVPII. LCPII is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker, a member of the Issuer’s board of directors and Patrick G. Enright, are the managing members of LCPII and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 33,981,877 shares of Common Stock outstanding as of April 28, 2023, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 78349D107    13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Longitude Prime Partners, LLC

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      0

         8  

      SHARED VOTING POWER

     

      980,000 (1)

         9  

      SOLE DISPOSITIVE POWER

     

      0

       10  

      SHARED DISPOSITIVE POWER

     

      980,000 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      980,000 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      2.9% (2)

    14  

      TYPE OF REPORTING PERSON (see instructions)

     

      OO

     

    (1)

    All shares of Common Stock are held of record by LPF (as defined in Item 2(a) below). LPP (as defined in Item 2(a) below) is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker, a member of the Issuer’s board of directors and Patrick G. Enright, are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 33,981,877 shares of Common Stock outstanding as of April 28, 2023, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 78349D107    13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Longitude Prime Fund, L.P.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

     

      WC

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      0

         8   

      SHARED VOTING POWER

     

      980,000 (1)

         9   

      SOLE DISPOSITIVE POWER

     

      0

       10   

      SHARED DISPOSITIVE POWER

     

      980,000 (1)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      980,000 (1)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      2.9% (2)

    14  

      TYPE OF REPORTING PERSON (see instructions)

     

      PN

     

    (1)

    All shares of Common Stock are held of record by LPF. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to these securities. Juliet Tammenoms Bakker, a member of the Issuer’s board of directors and Patrick G. Enright, are the managing members of LPP and may each be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Based on 33,981,877 shares of Common Stock outstanding as of April 28, 2023, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 78349D107    13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Patrick G. Enright

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      33,135 (1)

         8   

      SHARED VOTING POWER

     

      2,471,463 (2)

         9   

      SOLE DISPOSITIVE POWER

     

      33,135 (1)

       10   

      SHARED DISPOSITIVE POWER

     

      2,471,463 (2)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,504,598 (1)(2)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      7.4% (3)

    14  

      TYPE OF REPORTING PERSON (see instructions)

     

      IN

     

    (1)

    All shares of Common Stock are held of record by Patrick G. Enright.

    (2)

    Consists of (i) 1,491,463 shares of Common Stock held of record by LVPII and (ii) 980,000 shares of Common Stock held of record by LPF. LCPII is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to the shares held of record by LVPII. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the shares held by LPF. Juliet Tammenoms Bakker, a member of the Issuer’s board of directors and Patrick G. Enright, are the managing members of LCPII and LPP and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVPII and LPF.

    (3)

    Based on 33,981,877 shares of Common Stock outstanding as of April 28, 2023, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 78349D107    13D   

     

      1    

      NAMES OF REPORTING PERSONS

     

      Juliet Tammenoms Bakker

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

      (a)  ☐        (b)  ☒

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (see instructions)

     

      AF

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      67,574 (1)

         8   

      SHARED VOTING POWER

     

      2,471,463 (2)

         9   

      SOLE DISPOSITIVE POWER

     

      67,574 (1)

       10   

      SHARED DISPOSITIVE POWER

     

      2,471,463 (2)

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,539,037 (1) (2)

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11

     

      7.5% (3)

    14  

      TYPE OF REPORTING PERSON (see instructions)

     

      IN

     

    (1)

    All shares of Common Stock are held of record by Juliet Tammenoms Bakker.

    (2)

    Consists of (i) 1,491,463 shares of Common Stock held of record by LVPII and (ii) 980,000 shares of Common Stock held of record by LPF. LCPII is the general partner of LVPII and may be deemed to have voting, investment and dispositive power with respect to the shares held of record by LVPII. LPP is the general partner of LPF and may be deemed to have voting, investment and dispositive power with respect to the shares held by LPF. Juliet Tammenoms Bakker, a member of the Issuer’s board of directors and Patrick G. Enright, are the managing members of LCPII and LPP and may each be deemed to share voting, investment and dispositive power with respect to the shares held by LVPII and LPF.

    (3)

    Based on 33,981,877 shares of Common Stock outstanding as of April 28, 2023, as reported by the Issuer in its Form 10-Q.


    CUSIP No. 78349D107    13D   

     

    Item 1. Security and Issuer.

    This joint statement on Schedule 13D/A (this “Statement”) is filed with respect to the Common Stock, par value $0.001 per share (“Common Stock”), of RxSight, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 100 Columbia, Aliso Viejo, CA 92656.

    Item 2. Identity and Background.

    (a) This Amendment No. 1 (“Amendment”) is being filed by Longitude Venture Partners II, L.P. (“LVPII”), Longitude Capital Partners II, LLC (“LCPII”), Longitude Prime Fund, L.P. (“LPF”), Longitude Prime Partners, LLC (“LPP” and together with LVPII, LCPII and LPF, the “Reporting Entities”) and Juliet Tammenoms Bakker (“Tammenoms Bakker”), a member of the Issuer’s board of directors (the “Board”) and Patrick G. Enright (“Enright” and together with Tammenoms Bakker, the “Reporting Individuals”). This Amendment amends and supplements the Schedule 13D originally filed with the Commission on August 13, 2021 (the “Original Schedule 13D”). The Reporting Entities and the Reporting Individuals are collectively referred to as the “Reporting Persons.” The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to the Original Schedule 13D as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person. Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

    Item 5. Interest in Securities of the Issuer.

    Item 5 of the Original Schedule 13D is hereby amended to add the following language:

    (a) and (b) See Items 7-11 of the cover pages of this Amendment and Item 2 above.

    (c)

    On May 26, 2023, LVPII effected a pro rata distribution without additional consideration of 497,150 shares of Common Stock to (i) LCPII, its general partner and (ii) its limited partners. LCPII then effected a pro rata distribution without additional consideration of the shares that it received in connection with such distribution to its members.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: June 5, 2023

     

    LONGITUDE VENTURE PARTNERS II, L.P.
    By: LONGITUDE CAPITAL PARTNERS II, LLC
    Its: General Partner
    By:  

    /s/ Cristiana Blauth Oliveira

      Cristiana Blauth Oliveira, Authorized Signatory

     

    LONGITUDE CAPITAL PARTNERS II, LLC
    By:  

    /s/ Cristiana Blauth Oliveira

      Cristiana Blauth Oliveira, Authorized Signatory

    /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright

    Patrick G. Enright

    /s/ Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker

    Juliet Tammenoms Bakker

     

    LONGITUDE PRIME FUND, L.P.
    By: LONGITUDE PRIME PARTNERS, LLC
    Its: General Partner
    By:  

    /s/ Cristiana Blauth Oliveira

      Cristiana Blauth Oliveira, Authorized Signatory
    LONGITUDE PRIME PARTNERS, LLC
    By:  

    /s/ Cristiana Blauth Oliveira

      Cristiana Blauth Oliveira, Authorized Signatory
    Get the next $RXST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXST

    DatePrice TargetRatingAnalyst
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    4/15/2025$18.00Neutral
    Piper Sandler
    4/9/2025$16.00Buy → Neutral
    UBS
    4/4/2025$40.00 → $17.00Overweight → Underweight
    Analyst
    4/3/2025$36.00 → $22.00Buy → Underperform
    BofA Securities
    12/20/2024$65.00 → $40.00Buy → Hold
    Stifel
    12/11/2024$56.00 → $42.00Overweight → Equal Weight
    Wells Fargo
    12/6/2024$52.00Buy
    UBS
    More analyst ratings

    $RXST
    Financials

    Live finance-specific insights

    See more
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

      ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company's investor relations web

      4/23/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

      ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Results Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, representing growth of 28% compared to the prior year period, and a decrease of 6% compared to the fourth quarter of 2024, driven by: The sale

      4/2/25 8:00:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      1/17/25 7:08:42 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Corley Jesse Anderson bought $1,014,570 worth of shares (22,476 units at $45.14), increasing direct ownership by 18% to 38,438 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      11/14/24 7:14:14 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      5/21/24 4:11:17 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $RXST
    Leadership Updates

    Live Leadership Updates

    See more
    • RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

      ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum. RxSight's management is scheduled to participate in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin

      5/20/25 4:10:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Present at the Bank of America Healthcare Conference

      ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas. RxSight's management is scheduled to present on Wednesday, May 14, 2025, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized visio

      4/30/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors

      ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig

      1/4/22 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RxSight upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded RxSight from Equal Weight to Overweight and set a new price target of $25.00

      5/19/25 8:47:30 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Piper Sandler initiated coverage on RxSight with a new price target

      Piper Sandler initiated coverage of RxSight with a rating of Neutral and set a new price target of $18.00

      4/15/25 9:02:26 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by UBS with a new price target

      UBS downgraded RxSight from Buy to Neutral and set a new price target of $16.00

      4/9/25 8:36:59 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    SEC Filings

    See more
    • SEC Form SD filed by RxSight Inc.

      SD - RxSight, Inc. (0001111485) (Filer)

      5/20/25 4:30:10 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by RxSight Inc.

      10-Q - RxSight, Inc. (0001111485) (Filer)

      5/7/25 4:15:25 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RxSight, Inc. (0001111485) (Filer)

      5/7/25 4:10:09 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/14/24 5:46:12 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 4:50:57 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 9:40:27 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Thunen Shelley B exercised 7,792 shares at a strike of $4.34, increasing direct ownership by 25% to 38,354 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      4/15/25 8:57:36 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Fountain Tamara sold $180,002 worth of shares (7,000 units at $25.71), decreasing direct ownership by 22% to 24,793 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      3/13/25 4:46:51 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Officer Weinberg Eric

      4 - RxSight, Inc. (0001111485) (Issuer)

      2/27/25 8:06:48 PM ET
      $RXST
      Ophthalmic Goods
      Health Care